HemaCare is the leading global provider of human-derived cellular material, supplying controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. HemaCare supports biotechnology and pharmaceutical companies, academic institutions, and research organization who rely on high-quality, viable, and functional human primary cells and blood components for biomedical and drug discovery research and cell therapy development.
News and Events
- Phacilitate Cell & Gene Therapy World
HemaCare will be attending and presenting at Phacilitate: Cell and Gene Therapy World. Be sure to meet up with Dr. Dominic Clarke to discuss your cell therapy needs.READ MORE
- HemaCare Details Expanded GMP Capabilities at CAR-TCR Summit in Boston, MAFacility Relocation and Expansion Offers Fully-Integrated GMP Cell Therapy ServicesREAD MORE
- HemaCare Reports First Half 2018 ResultsHemaCare reports on operational highlights and financial results for the six months ended June 30, 2018READ MORE
- HemaCare Expands Development of Cellular Therapy Services by Bolstering Scientific Team with Two Strategic New HiresIndustry mavens strengthen HemaCare’s expertise in cell therapy and bioprocessingREAD MORE
Investor Relations Contact Information
(877) 310-0717 (option 8)
250 Royall Street
Canton, MA 02021
The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control, with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
HemaCare voluntarily delisted from NASDAQ in 2012 due to the significant costs of remaining a public company and is no longer required to be registered with the SEC. HemaCare is currently traded on the OTCMKTS (Pink Sheets) under “HEMA”.
Note: It is the policy of HemaCare not to respond to email inquiries via return email. If you have a specific question regarding HemaCare, please call.